Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
H287635-5mg | 5mg | In stock | $44.90 | |
H287635-10mg | 10mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $69.90 | |
H287635-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $279.90 | |
H287635-100mg | 100mg | In stock | $429.90 | |
H287635-250mg | 250mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $799.90 |
STING antagonist
Synonyms | 1-(4-ethylphenyl)-3-(1H-indol-3-yl)urea | 3-(4-ethylphenyl)-1-(1H-indol-3-yl)urea | N-(4-ethylphenyl)-N'-1H-indol-3-yl-urea | H-151 |
---|---|
Specifications & Purity | Moligand™, ≥98%(HPLC) |
Biochemical and Physiological Mechanisms | H-151 is an irreversible antagonist of the stimulator of interferon genes (STING) protein, a central signalling component of the cytosolic DNA sensing pathway. Although STING is a vital component of the innate immune pathways, it has also been shown to ha |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | ANTAGONIST |
Mechanism of action | Antagonist of stimulator of interferon response cGAMP interactor 1 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
IUPAC Name | 1-(4-ethylphenyl)-3-(1H-indol-3-yl)urea |
---|---|
INCHI | InChI=1S/C17H17N3O/c1-2-12-7-9-13(10-8-12)19-17(21)20-16-11-18-15-6-4-3-5-14(15)16/h3-11,18H,2H2,1H3,(H2,19,20,21) |
InChi Key | UJZDIKVQFMCLBE-UHFFFAOYSA-N |
Canonical SMILES | CCC1=CC=C(C=C1)NC(=O)NC2=CNC3=CC=CC=C32 |
Isomeric SMILES | CCC1=CC=C(C=C1)NC(=O)NC2=CNC3=CC=CC=C32 |
PubChem CID | 7616033 |
Molecular Weight | 279.34 |
PubChem CID | 7616033 |
---|---|
CAS Registry No. | 941987-60-6 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
J2120385 | Certificate of Analysis | Aug 14, 2024 | H287635 |
J2120383 | Certificate of Analysis | Aug 09, 2024 | H287635 |
D2423369 | Certificate of Analysis | Apr 11, 2024 | H287635 |
D2423371 | Certificate of Analysis | Apr 11, 2024 | H287635 |
D2423372 | Certificate of Analysis | Apr 11, 2024 | H287635 |
D2423373 | Certificate of Analysis | Apr 11, 2024 | H287635 |
D2423374 | Certificate of Analysis | Apr 11, 2024 | H287635 |
D2423375 | Certificate of Analysis | Apr 11, 2024 | H287635 |
D2423376 | Certificate of Analysis | Apr 11, 2024 | H287635 |
D2423377 | Certificate of Analysis | Apr 11, 2024 | H287635 |
D2315353 | Certificate of Analysis | Jun 29, 2021 | H287635 |
Solubility | Insoluble in water,Dissolved in DMSO, maximum concentration (mg/ml): 125, maximum concentration (mm): 447.48 (ultrasonic treatment required) |
---|
Pictogram(s) | GHS07 |
---|---|
Signal | Warning |
Hazard Statements | H315:Causes skin irritation H319:Causes serious eye irritation H335:May cause respiratory irritation |
Precautionary Statements | P261:Avoid breathing dust/fume/gas/mist/vapors/spray. P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing. |
Starting at $25.90
Starting at $195.90
Starting at $210.90
1. Xiaohua Xie, Xiaofeng Wu, Dongsheng Zhao, Ying Liu, Qiyue Du, Yitian Li, Yaping Xu, Yuhang Li, Yan Qiu, Yungang Yang. (2023) Fluvoxamine alleviates bleomycin-induced lung fibrosis via regulating the cGAS-STING pathway. PHARMACOLOGICAL RESEARCH, 187 (106577). [PMID:36435270] |
1. Haag SM, Gulen MF, Reymond L, Gibelin A, Abrami L, Decout A, Heymann M, van der Goot FG, Turcatti G, Behrendt R et al.. (2018) Targeting STING with covalent small-molecule inhibitors.. Nature, 559 (7713): (269-273). [PMID:29973723] |
2. Di Domizio J, Gulen MF, Saidoune F, Thacker VV, Yatim A, Sharma K, Nass T, Guenova E, Schaller M, Conrad C et al.. (2022) The cGAS-STING pathway drives type I IFN immunopathology in COVID-19.. Nature, 129 (3): (589-97). [PMID:35045565] |
3. Xiaohua Xie, Xiaofeng Wu, Dongsheng Zhao, Ying Liu, Qiyue Du, Yitian Li, Yaping Xu, Yuhang Li, Yan Qiu, Yungang Yang. (2023) Fluvoxamine alleviates bleomycin-induced lung fibrosis via regulating the cGAS-STING pathway. PHARMACOLOGICAL RESEARCH, 187 (106577). [PMID:36435270] |